Summary
Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Pipeline Review, H2 2016’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Daiichi Sankyo Company, Limited
Genelux Corporation
Immune Pharmaceuticals Inc.
Millennium Pharmaceuticals Inc
Novartis AG
Pfizer Inc.
Plexxikon Inc.
Trophogen, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Thyroid Cancer - Overview 8
Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9
Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10
Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anaplastic Thyroid Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Anaplastic Thyroid Cancer - Products under Development by Companies 14
Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16
Daiichi Sankyo Company, Limited 16
Genelux Corporation 17
Immune Pharmaceuticals Inc. 18
Millennium Pharmaceuticals Inc 19
Novartis AG 20
Pfizer Inc. 21
Plexxikon Inc. 22
Trophogen, Inc. 23
Anaplastic Thyroid Cancer - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ceritinib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CLM-3 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
crizotinib - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
crolibulin - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
efatutazone - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
GLONC-2 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GLV-1h153 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
pexidartinib - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
PLX-8394 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
sapanisertib - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
utomilumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Anaplastic Thyroid Cancer - Dormant Projects 70
Anaplastic Thyroid Cancer - Product Development Milestones 71
Featured News & Press Releases 71
Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73
List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 16
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H2 2016 17
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2016 18
Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 19
Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H2 2016 20
Anaplastic Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016 21
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2016 22
Anaplastic Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Assessment by Combination Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Anaplastic Thyroid Cancer - Dormant Projects, H2 2016 70
List of Figures
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
